Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s Why

by · The Cerbat Gem

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $35.24, but opened at $33.45. Nanobiotix shares last traded at $32.6720, with a volume of 24,122 shares traded.

Analyst Ratings Changes

Several equities research analysts recently issued reports on NBTX shares. Guggenheim initiated coverage on Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, Leerink Partners lifted their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 4th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

View Our Latest Report on Nanobiotix

Nanobiotix Stock Performance

The firm has a 50 day simple moving average of $38.90 and a two-hundred day simple moving average of $37.40.

Nanobiotix Company Profile

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.

Featured Stories